Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
Year: 2021
Type: article
Study design: Clinical Trial
Abstract: Purpose Intravenous trastuzumab, pertuzumab, and docetaxel are first-line standard of care for patients with HER2-positive metastatic breast cancer (mBC). MetaPHER is the first study assessing the safety and tolerability of subcutaneous trastuzumab plus intravenous pertuzumab and chemotherapy in a global patient population with HER2-positive mBC. Methods In this open-label, single-arm, multicenter, phase 3b study, eligible patients were ≥ 18 years old with histologically/cytologically confirmed previously untreated HER2-positive mBC. All received ≥ 1 subcutaneous trastuzumab 600 mg fixed dose plus intravenous pertuzumab (loading dose: 840 mg/kg; maintenance: 420 mg/kg) and docetaxel (≥ 6 cycles; initial dose 75 mg/m 2 ) every 3 weeks. The primary objective was safety and tolerability; secondary objectives included efficacy. Results At clinical cutoff, 276 patients had completed the study; median duration of follow-up was 27 months. The most common any-grade adverse events were diarrhea, alopecia, and asthenia; the most common grade ≥ 3 events were neutropenia, febrile neutropenia, and hypertension. There were no cardiac deaths and mean left ventricular ejection fraction was stable over time. Median investigator-assessed progression-free survival was 18.7 months; objective response rate was 75.6%. Conclusions Safety and efficacy with subcutaneous trastuzumab plus intravenous pertuzumab and docetaxel in mBC are consistent with historical evidence of intravenous trastuzumab with this combination. Findings further support subcutaneous administration not affecting safety/efficacy profiles of trastuzumab in HER2-positive BC with increased flexibility in patient care. A fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection has recently been approved for the treatment of HER2-positive early/mBC, further addressing the increasing relevance of and need for patient-centric treatment strategies. Trial registration NCT02402712
Authors: Sherko Kuemmel, Carlo A. Tondini, Jacinta Abraham, Zbigniew Nowecki, Bartosz Itrych, Erika Hitre, Bogusława Karaszewska, Alejandro Juárez-Ramiro, Flavia Morales-Vásquez, Jose Manuel Pérez-García, Servando Cardona-Huerta, Estefania Monturus, Marco Sequi, Eleonora Restuccia, Mark Benyunes, Miguel Martín
Institutions: Kliniken Essen-Mitte, Charité – Universitätsmedizin Berlin, Ospedale Papa Giovanni XXIII, Velindre Cancer Centre, The Maria Sklodowska-Curie National Research Institute of Oncology, Central Clinical Hospital, National Institute of Oncology, Instituto Nacional de Cancerología, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Hospital Zambrano Hellion, Tecnológico de Monterrey, F. Hoffmann-La Roche AG, Genentech, Universidad Complutense de Madrid, Centro de Investigación Biomédica en Red de Cáncer, Instituto de Investigación Sanitaria Gregorio Marañón
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,860
Funder: Roche
OpenAlex ID: W3137191916
